GR1005865B - Νεοι συνδετες των σιγμα υποδοχεων με αντι-αποπτωτικες και/η προ-αποπτωτικες ιδιοτητες επι των κυτταρικων βιοχημικων μηχανισμων, με νευρο-προστατευτικη, αντικαρκινικη, αντι-μεταστατικη και αντι- αντι-(χρονιο)φλεγμονικη δραση. - Google Patents

Νεοι συνδετες των σιγμα υποδοχεων με αντι-αποπτωτικες και/η προ-αποπτωτικες ιδιοτητες επι των κυτταρικων βιοχημικων μηχανισμων, με νευρο-προστατευτικη, αντικαρκινικη, αντι-μεταστατικη και αντι- αντι-(χρονιο)φλεγμονικη δραση.

Info

Publication number
GR1005865B
GR1005865B GR20070100020A GR20070100020A GR1005865B GR 1005865 B GR1005865 B GR 1005865B GR 20070100020 A GR20070100020 A GR 20070100020A GR 20070100020 A GR20070100020 A GR 20070100020A GR 1005865 B GR1005865 B GR 1005865B
Authority
GR
Greece
Prior art keywords
apoptotic
neuroprotective
metastatic
pro
cancer
Prior art date
Application number
GR20070100020A
Other languages
English (en)
Inventor
Αλεξανδρος Βαμβακιδης
Original Assignee
Anavex Life Sciences Corp.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anavex Life Sciences Corp. filed Critical Anavex Life Sciences Corp.
Priority to GR20070100020A priority Critical patent/GR1005865B/el
Priority to RU2009125211/15A priority patent/RU2497511C2/ru
Priority to PCT/GR2008/000002 priority patent/WO2008087458A2/en
Priority to EP08702158A priority patent/EP2164479A2/en
Priority to US12/522,761 priority patent/US20100069484A1/en
Priority to CN200880002334A priority patent/CN101646430A/zh
Publication of GR1005865B publication Critical patent/GR1005865B/el
Priority to US13/777,471 priority patent/US20170129864A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/10—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/14—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Abstract

Η εφεύρεση αφορά νέους πρωτότυπους συνδέτες των υποδοχέων σίγμα : (Μονο - ή διαλκυλαμινοαλκυλ) - γ - βουτυρολακτόνες, τα ανάλογα τους αμινοτετραϋδροφουράνια, οι (1 - αδαμαντυλ) φαινύλ αλκυλαμίνες, οιΝ,Ν Διαλκυλ α-(αδαμαντυλ - 1) βενζυλοξυ - 2) αλκυλαμίνες και οι 3 - κυκλοπεντυλ αδαμαντυλ - αμίνες ή - αλκυλαμίνες ή - αλκυλ φαινυλαμίνες, τα εναντιομερή τους ή τα διαστερεοϊσομερή τους και τα φαρμακευτικώς αποδεκτά τους άλατα, με προ-αποπτωτικές και αντι-αποπτωτικές ιδιότητες επί των κυτταρικών βιοχημικών μηχανισμών, και με αντικαρκινική, αντιμεταστατική, αντι-(χρονιό) φλεγμονική, νευροπροστατευτική, αντισπασμωδική, αντικαταθλιπτική και νοοαναληπτική ή καταπραϋντική δράση.
GR20070100020A 2007-01-17 2007-01-17 Νεοι συνδετες των σιγμα υποδοχεων με αντι-αποπτωτικες και/η προ-αποπτωτικες ιδιοτητες επι των κυτταρικων βιοχημικων μηχανισμων, με νευρο-προστατευτικη, αντικαρκινικη, αντι-μεταστατικη και αντι- αντι-(χρονιο)φλεγμονικη δραση. GR1005865B (el)

Priority Applications (7)

Application Number Priority Date Filing Date Title
GR20070100020A GR1005865B (el) 2007-01-17 2007-01-17 Νεοι συνδετες των σιγμα υποδοχεων με αντι-αποπτωτικες και/η προ-αποπτωτικες ιδιοτητες επι των κυτταρικων βιοχημικων μηχανισμων, με νευρο-προστατευτικη, αντικαρκινικη, αντι-μεταστατικη και αντι- αντι-(χρονιο)φλεγμονικη δραση.
RU2009125211/15A RU2497511C2 (ru) 2007-01-17 2008-01-14 Новые лиганды сигма (σ)-рецепторов с антиапоптотическими и/или проапоптотическими свойствами в отношении биохимических механизмов клетки, обладающие нейропротекторным, противораковым, антиметастатическим и противовоспалительным действием при хроническом воспалительном процессе
PCT/GR2008/000002 WO2008087458A2 (en) 2007-01-17 2008-01-14 NEW SIGMA(σ)-RECEPTOR LIGANDS WITH ANTI-APOPTOTIC AND/OR PRO-APOPTOTIC PROPERTIES OVER CELLULAR BIOCHEMICAL MECHANISMS, WITH NEUROPROTECTIVE, ANTI-CANCER, ANTI-METASTATIC AND ANTI-(CHRONIC) INFLAMMATORY ACTION
EP08702158A EP2164479A2 (en) 2007-01-17 2008-01-14 New sigma-receptor ligands with anti-apoptotic and/or pro-apoptotic properties over cellular biochemical mechanisms, with neuroprotective, anti- cancer, anti-metastatic and anti-(chronic) inflammatory action
US12/522,761 US20100069484A1 (en) 2007-01-17 2008-01-14 SIGMA(s)-RECEPTOR LIGANDS WITH ANTI-APOPTOTIC AND/OR PRO-APOPTOTIC PROPERTIES OVER CELLULAR BIOCHEMICAL MECHANISMS, WITH NEUROPROTECTIVE, ANTI-CANCER, ANTI-METASTATIC AND ANTI-(CHRONIC) INFLAMMATORY ACTION
CN200880002334A CN101646430A (zh) 2007-01-17 2008-01-14 具有基于细胞生化机制的抗凋亡和/或促凋亡特性，并具有神经保护、抗癌、抗转移以及抗(慢性)炎症作用的新型σ－受体配体
US13/777,471 US20170129864A1 (en) 2007-01-17 2013-02-26 New sigma-receptors ligands with anti-apoptotic and/or pro-apoptotic properties, over cellular biochemical mechanisms with neuroprotective, anti-cancer, anti-metastatic and anti-(chronic) inflammatory action

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GR20070100020A GR1005865B (el) 2007-01-17 2007-01-17 Νεοι συνδετες των σιγμα υποδοχεων με αντι-αποπτωτικες και/η προ-αποπτωτικες ιδιοτητες επι των κυτταρικων βιοχημικων μηχανισμων, με νευρο-προστατευτικη, αντικαρκινικη, αντι-μεταστατικη και αντι- αντι-(χρονιο)φλεγμονικη δραση.

Publications (1)

Publication Number Publication Date
GR1005865B true GR1005865B (el) 2008-04-07

Family

ID=39187830

Family Applications (1)

Application Number Title Priority Date Filing Date
GR20070100020A GR1005865B (el) 2007-01-17 2007-01-17 Νεοι συνδετες των σιγμα υποδοχεων με αντι-αποπτωτικες και/η προ-αποπτωτικες ιδιοτητες επι των κυτταρικων βιοχημικων μηχανισμων, με νευρο-προστατευτικη, αντικαρκινικη, αντι-μεταστατικη και αντι- αντι-(χρονιο)φλεγμονικη δραση.

Country Status (6)

Country Link
US (2) US20100069484A1 (el)
EP (1) EP2164479A2 (el)
CN (1) CN101646430A (el)
GR (1) GR1005865B (el)
RU (1) RU2497511C2 (el)
WO (1) WO2008087458A2 (el)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR1006794B (el) 2009-02-26 2010-06-04 Αλεξανδρος Βαμβακιδης Προσδετες των σιγμα υποδοχεων, αντι-αποπτωτικες και προ-αποπτωτικες ιδιοτητες επι των κυτταρικων μηχανισμων, και με πρωτοτυπη κυτταρο-προστατευτικη αλλα και αντικαρκινικη δραση
GR1007322B (el) * 2010-03-09 2011-06-22 Βαμβακιδης, Αλεξανδρος Δημητριου Συνθεση της 1-μεθυλο-4-[4,4-διφαινυλο-4-(1-αδαμαντυλο-βουτυλο] πιπεραζινης και δομικων της αναλογων με αντικαρκινικες ιδιοτητες
WO2011143444A2 (en) * 2010-05-14 2011-11-17 President And Fellows Of Harvard College Diphenylbutypiperidine autophagy inducers
JP6260531B2 (ja) 2012-05-17 2018-01-17 Jsr株式会社 酸拡散制御剤、感放射線性樹脂組成物及びレジストパターン形成方法
EP2852388A4 (en) 2012-05-23 2016-01-13 Univ Johns Hopkins COMPOUNDS AND METHOD FOR USE THEREOF FOR THE TREATMENT OF NEURODEEGENERATIVE DISEASES
GR1008233B (el) 2013-03-28 2014-06-23 Αλεξανδρος Δημητριου Βαμβακιδης Βελτιωση και θεραπευτικη αξιοποιηση της συμπτωματικης αντιμετωπισης της ασθενειας του alzheimer με rivastigmine, galantamine ή donepezil, δια επιλεγμενων αμινοτετραϋδροφουρανιων που δρουν σαν μικτοι σιγμα-1/ μουσκαρινικοι προσδετες
WO2016064711A1 (en) 2014-10-20 2016-04-28 Anavex Life Sciences Corp. A 19-144, a2-73 and certain anticholinesterase inhibitor compositions and method for anti-seizure therapy
US10507196B2 (en) 2016-01-26 2019-12-17 Anavex Life Sciences Corp. Neurodevelopmental disorder therapy
JP7332590B2 (ja) * 2017-10-20 2023-08-23 アナベックス ライフ サイエンス コーポレイション 心臓機能障害の治療
EP4314011A1 (en) * 2021-03-24 2024-02-07 Anavex Life Sciences Corp. Prevention and treatment of coronavirus infection

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR1002616B (el) * 1996-02-21 1997-02-20 Συνθεση και μεθοδος συνθεσης μοριου: τετραυδρο-ν,ν-διμεθυλο-2,2-διφαινυλο-3-φουρανομεθαναμινης (αε 37), αντισπασμωδικης, αντικαταθλιπτικης και νοοτροπικης δρασης.
FR2794742B1 (fr) * 1999-06-11 2005-06-03 Sanofi Synthelabo Nouveaux derives du benzene, un procede pour leur preparation et les compositions pharmaceutiques les contenant
GR1004208B (en) * 2001-10-15 2003-04-04 Αλεξανδρος Βαμβακιδης Aminotetrahydrofuran derivatives, muscarinic/sigma/sodium channel ligands, with synergic sigma/muscarinic (neuroactivating) and sigma/sodium channel (neuroprotective) components, as prototypical activating - neuroprotectors and neuroregenerative drugs
GR1004868B (el) * 2003-04-22 2005-04-26 Αλεξανδρος Βαμβακιδης Αμινοτετραυδροφουρανικα παραγωγα με τριπλη χημικη συγγενεια (μουσκαρινικη/σιγμα/υποδοχεων/ διαυλων νατριου) με ορθο- και αλλοστeρικη δραση σαν πρωτοτυπα νευρορυθμιστικα και νευροαναενωτικα φαρμακα.
FR2897535B1 (fr) * 2006-02-21 2012-07-20 Alexandre Vamvakides Les sigma ligands : (mono- ou di-alkylaminoalkyl)-y- butyrolactones, leurs analogues aminotetrodrafuranes et les (1-adamantyl) benzene(s) alkylamines en tant que modulateurs prototypiques des recepteurs cellulaires

Also Published As

Publication number Publication date
US20170129864A1 (en) 2017-05-11
EP2164479A2 (en) 2010-03-24
US20100069484A1 (en) 2010-03-18
WO2008087458A3 (en) 2008-12-11
RU2009125211A (ru) 2011-02-27
CN101646430A (zh) 2010-02-10
RU2497511C2 (ru) 2013-11-10
WO2008087458A2 (en) 2008-07-24

Similar Documents

Publication Publication Date Title
GR1005865B (el) Νεοι συνδετες των σιγμα υποδοχεων με αντι-αποπτωτικες και/η προ-αποπτωτικες ιδιοτητες επι των κυτταρικων βιοχημικων μηχανισμων, με νευρο-προστατευτικη, αντικαρκινικη, αντι-μεταστατικη και αντι- αντι-(χρονιο)φλεγμονικη δραση.
USD677326S1 (en) Type font
USD730985S1 (en) Alphabet zoo poster
USD678937S1 (en) Type font
USD687885S1 (en) Type font
BRPI0815409A2 (pt) Cepa bacteriana, processos para a produção fermentativa de um composto, e para a produção de um composto, e, uso de uma cepa bacteriana.
GB2487400B (en) Scoring balloon with offset scoring elements
ATE543644T1 (de) Fotopolymerisierbare flexodruckelemente und daraus hergestellte harte flexodruckformen
USD677324S1 (en) Type font
MX2010009645A (es) Derivados novedosos de aminometil benceno.
WO2007136811A3 (en) Exceptions grouping
NO20065907L (no) Nye tetrahydropyridotiofener
MY159222A (en) Method of partially replacing shell plate of tower or vessel
GT200600015S (es) Recipiente para ajo.
USD677323S1 (en) Type font
USD679746S1 (en) Type font
USD677327S1 (en) Type font
UA71704U (ru) Конструкция детской книги
TH36255S1 (th) ลวดลายแผ่นจักสาน
TH116355S (th) ลวดลายแผ่นจักสาน
TH116357S (th) ลวดลายแผ่นจักสาน
TH119306S (th) ลวดลายแผ่นจักสาน
TH122757S (th) ลวดลายแผ่นจักสาน
TH36258S1 (th) ลวดลายแผ่นจักสาน
TH36261S1 (th) ลวดลายแผ่นจักสาน

Legal Events

Date Code Title Description
PG Patent granted
ML Lapse due to non-payment of fees

Effective date: 20140801